Phoenix Financial Ltd. Acquires 564 Shares of Gilead Sciences, Inc. $GILD

Phoenix Financial Ltd. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 10,094 shares of the biopharmaceutical company’s stock after purchasing an additional 564 shares during the quarter. Phoenix Financial Ltd.’s holdings in Gilead Sciences were worth $1,119,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $215,000. GAMMA Investing LLC grew its position in shares of Gilead Sciences by 24.9% during the 1st quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock worth $2,550,000 after buying an additional 4,532 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of Gilead Sciences by 25.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 190,773 shares of the biopharmaceutical company’s stock worth $21,376,000 after buying an additional 38,530 shares during the period. Finally, Flagship Harbor Advisors LLC grew its position in shares of Gilead Sciences by 4.6% during the 1st quarter. Flagship Harbor Advisors LLC now owns 4,396 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 193 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GILD. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. Finally, Citigroup lifted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.14.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,500 shares of company stock worth $8,281,540 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $124.08 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock’s fifty day simple moving average is $115.35 and its two-hundred day simple moving average is $110.71. Gilead Sciences, Inc. has a 1-year low of $85.60 and a 1-year high of $124.61. The stock has a market cap of $153.96 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the business earned $2.01 EPS. The business’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.